Broccoli sprout beer?

This 2023 study investigated supplementing broccoli into beer:

“The objective of this work was to evaluate alternative broccoli materials (sprouts and by-products powder), which could be a sustainable dietary source of bioactive sulforaphane (SFN). Results showed high concentrations of SFN in beers supplemented with broccoli sprouts and powder (5.00 and 2.54 mg/L, respectively, previous to bottling), indicating that formation rate for SFN when adding sprouts and by-products powder were almost 38.5% and 19.5%, correspondingly. These concentrations remained stable until bottling, where they were reduced by >50%.


Beers supplemented with broccoli presented a higher alcohol content (6.6%, on average) than control beer, regardless of the broccoli material used. Sensory analysis revealed positive attributes (colour, floral, fruity, and aftertaste as a result of the profile of volatile compounds) of beers developed using sprouts. Future research is still needed to stabilize SFN during bottling.” “Broccoli products supplemented beers provide a sustainable source of dietary sulforaphane”


Week 144 of Changing to a youthful phenotype with sprouts

Two papers, starting with a 2023 study that investigated the same red radish cultivar as Sulforaphene, a natural analog of sulforaphane:

“Availability of microgreen products is constantly rising, i.e., they are offered for sale in local farmers markets, specialty stores, and in chain grocery stores. Due to the low demands required for their cultivation and easily available LED settings, microgreens are increasingly grown on a small scale in homes and after harvesting, they are stored in kitchen refrigerators at 4 °C.

The aim of this study was to simulate such cultivation and storage conditions to examine antioxidant capacity of home-grown radish microgreens. Seven-day-old radish microgreens, grown under purple and white LED light, were harvested and stored at 4 °C for two weeks.

Measurements of total antioxidant capacity and bioactive substances were conducted on the harvesting day and on the 3rd, 7th, and 14th day of storage. All three radish cultivars (Raphanus sativus L.) with different leaf colorations:

  • Purple radish (R. sativus cult. China Rose, cvP);
  • Red radish (R. sativus cult. Sango, cvR); and
  • Green radish (Raphanus sativus var. longipinnatus, Japanese white or daikon radish, cvG)

were purchased commercially from a local supplier.

The highest contents of total soluble phenolics, proteins, and sugars, dry matter, and monomeric anthocyanin content, as well as higher overall antioxidant capacity determined in the red radish cultivar (cvR), distinguished this cultivar as the most desirable for human consumption regardless of the cultivation light spectrum.” “Antioxidant Capacity and Shelf Life of Radish Microgreens Affected by Growth Light and Cultivars”

A 2021 review summarized what was known about radishes up to then. Here’s part of its Discussion section:

“It is worth considering radish’s organoleptic characteristics since its particular flavor can influence its acceptability among consumers. The main compound associated with its characteristic pungent flavor is raphasatin, which we have found to be the most reported isothiocyanate produced from the breakdown of glucoraphasatin.

Glucoraphasatin ranked as one of the most concentrated glucosinolates in radish, particularly in its sprouts, but also present in other parts like roots and seeds. Pungency differs among radish cultivars, environmental growth factors, agronomic, and cooking practices.”

1-s2.0-S0924224421003058-gr3_lrg “Nutritional and phytochemical characterization of radish (Raphanus sativus): A systematic review”

Seeds I’ve sprouted this year so far, left to right – red radish (Sango), broccoli, red cabbage (Red Acre), yellow mustard, oat (Avena sativa):


Red radish had similar growth characteristics as broccoli. Started with 3.6 grams of seeds, which increased to 22.2 g after three days using the same soaking and rinsing protocol I use for other sprouts.


The taste of red radish was too sharp for me to eat by themselves, so I combined them with my broccoli / red cabbage / mustard sprout mix. Bumped up microwaving time to 48 seconds in a 1000 W microwave while staying short of the 60°C (140°F) myrosinase cliff.

The whole mix still had a strong radish taste, though. It was as if two whole red radishes were sliced into a small salad.

Can’t add anything more to dampen that taste and expect beneficial compounds to be unaffected. From Week 19:

A 2018 Netherlands study Bioavailability of Isothiocyanates From Broccoli Sprouts in Protein, Lipid, and Fiber Gels found:

Compared to the control broccoli sprout, incorporation of sprouts in gels led to lower bioavailability for preformed sulforaphane and iberin.”

IAW, eating protein, fats, and fiber along with microwaved broccoli sprouts wouldn’t help. A 2018 review with some of the same researchers Isothiocyanates from Brassica Vegetables-Effects of Processing, Cooking, Mastication, and Digestion offered one possible explanation for protein acting to lower broccoli sprout compounds’ bioavailability:

“In vitro studies show that ITCs can potentially react with amino acids, peptides, and proteins, and this reactivity may reduce the ITC bioavailability in protein‐rich foods. More in vivo studies should be performed to confirm the outcome obtained in vitro.”

Mixing in red radish sprouts also gave me an upset stomach five of the six mornings. So I won’t continue to sprout red radish.

That said, I’d definitely consider sprouting red radish again to accelerate isothiocyanate treatment of problems where symptoms are much worse than an upset stomach, such as:

  • Neurogenerative diseases with their cognitive decline;
  • Immune system disorders;
  • Bacterial and viral infections; and
  • Other damage caused by oxidative stress conditions in eyes, vascular system, kidney function, etc.

Piping in the New Year


Sulforaphene, a natural analog of sulforaphane

Three papers on sulforaphene, starting with a 2022 in vitro digestion study by Our model clinical trial for Changing to a youthful phenotype with broccoli sprouts group:

“This work aims to assess anti-inflammatory potential of bioactive compounds of cruciferous sprouts red radish (RRS) and red cabbage (RCS) in their bioaccessible form (obtained by the digestion of aqueous extracts). We used a well-established in vitro inflammation cellular model consisting of human macrophage-like HL60 cells stimulated with LPS, which mimics systemic chronic inflammatory conditions present in certain non-communicable diseases such as cardiovascular disease, cancer, and diabetes.


Composition of RRS and RCS digestates extracts presented differences with a 20% lower content of total isothiocyanates (ITCs) in RRS than in RCS. However, there was more variability in the compounds present in RRS than in RCS extract digestates, including sulforaphene (SFE) and 3,3′-diindolylmethane (DIM), which were exclusively present in RRS.

RCS extract showed a trend of decreasing both TNF-α and IL-6 production under LPS-stimulated conditions, and this inhibitory effect was mainly observed at final protein expression. This activity at higher rates might be related to the inhibitory ability of iberin upon TLRs dimerization, impairing the NF-κB signaling pathway.

On the other hand, RRS exhibited a significant dose–response inhibition of IL-6 production levels. This difference in better performance of RRS compared to RCS could be exerted by the higher concentration of sulforaphane, and the exclusive presence of SFE, DIM, and anthocyanins in RRS.” “Anti-inflammatory potential of digested Brassica sprout extracts in human macrophage-like HL-60 cells”

I was surprised that this study didn’t detect anthocyanins in 8-day-old red cabbage sprout digestates, as they are visibly present in red cabbage sprouts. For example, from Week 56:


Reference 32 of this study was a 2021 review:

“Sulforaphene (SRP), as a product derived from glucoraphenin in the presence of myrosinase, mainly exists in cruciferous plants, especially in dried and mature seeds of radish. The most abundant ITC in juice of R. sativus L. coming from Sango freeze-dried sprouts is SRP. There is no safe and efficient SRP chemical synthesis which could be industrialized.

Structural variation in ITCs, such as the presence of particular functional group, molecular size, and length of a hydrocarbon chain, often results in very diverse antimicrobial activities. SRP, which is similar to sulforaphane in chemical structure but has an extra double bond, shows a much higher antimicrobial activity. However, the exact explanation for this enhanced microbial activity remains unknown.” “Sulforaphene: Formation, stability, separation, purification, determination and biological activities” (not freely available) Thanks to Dr. Jie Zhang for providing a copy.

Eat broccoli sprouts instead of antibiotics had two papers on ITCs’ antimicrobial actions.

A third paper was a 2022 cell study:

“Acne is a chronic inflammatory disease of the sebaceous gland attached to hair follicles. Cutibacterium acnes is a major cause of inflammation caused by acne.

It is well known that C. acnes secretes a lipolytic enzyme to break down lipids in sebum, and free fatty acids produced at this time accelerate the inflammatory reaction. There are several drugs used to treat acne; however, each one has various side effects.

We examined effects of sulforaphene (SFEN) on bacterial growth and inflammatory cytokine production induced by C. acnes. SFEN showed antibacterial activity against C. acnes and controlled the inflammatory response on keratinocytes and monocytes. This finding means that SFEN has potential as both a cosmetic material for acne prevention and a pharmaceutical material for acne treatment.” “Sulforaphene Attenuates Cutibacterium acnes-Induced Inflammation”

I ordered the Sango variety of red radish seeds used in this first study, to arrive in two weeks. I expect that their flavor and sulforaphene combination will be a good substitute for the mainly-flavor mustard third of my 3-day-old sprouts brocolli / red cabbage / mustard sprouts morning mix.

Home sprouting cupboard setup, with Avena sativa twice-daily hulled oats sprouts on top:


Do broccoli sprouts treat asthma?

This 2022 rodent study investigated sulforaphane’s effects on airway disease:

“Sulforaphane has been studied in numerous preclinical and clinical models of lung damage and airway diseases. The lack of definitive findings from clinical studies to date most likely reflects issues with extract preparations and dosage regimes.

We investigated effects of administration of L-sulforaphane (LSF), which is also known as (R)-sulforaphane, in a murine model of ovalbumin (OVA)-induced chronic allergic airways disease (AAD). This model of chronic AAD recapitulates several features of human asthma including airway inflammation, airway remodeling, and airway hyper-responsiveness.

Our findings confirmed the efficacy of LSF in attenuating pathologies associated with AAD, involving activation of antioxidant and anti-inflammatory pathways. Inhibition of HDAC enzymes by LSF and accumulation of acetylated core histones and α-tubulin in vivo following LSF administration represent an important epigenetic regulatory mechanism. LSF and its metabolites may modulate HDAC6 and HDAC8 enzymes by binding to the catalytic site.

sulforaphane asthma

Our findings along with accumulated evidence, highlight the clinical potential of sulforaphane as either a prophylactic or a therapeutic in the context of AAD.” “Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms” (not freely available)


Eat mushrooms every day?

Three 2022 papers on amino acid ergothioneine, starting with a human study:

“We examined temporal relationships between plasma ergothioneine (ET) status and cognition in a cohort of 470 elderly subjects attending memory clinics in Singapore. All participants underwent baseline plasma ET measurements as well as neuroimaging for cerebrovascular disease (CeVD) and brain atrophy. Neuropsychological tests of cognition and function were assessed at baseline and follow-up visits for up to five years.

Lower plasma ET levels were associated with poorer baseline cognitive performance and faster rates of decline in function as well as in multiple cognitive domains including memory, executive function, attention, visuomotor speed, and language. In subgroup analyses, longitudinal associations were found only in non-demented individuals.

Mediation analyses showed that effects of ET on cognition seemed to be largely explainable by severity of concomitant CeVD, specifically white matter hyperintensities, and brain atrophy. Our findings support further assessment of plasma ET as a prognostic biomarker for accelerated cognitive and functional decline in pre-dementia and suggest possible therapeutic and preventative measures.” “Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics”

Earlier this year, two of the study’s coauthors put together a collection of 11 ergothioneine papers:

“One catalyst for this upsurge of interest was the discovery in 2005 of a transporter for ET (OCTN1, often now called the ergothioneine transporter, ETT), which accounts for the fact that animals (including humans) take up and avidly retain ET from the diet. The presence of a specific transporter together with the avid retention of ET in the body implies that this compound is important to us.

To quote an old phrase ‘correlation does not imply causation.’ Low ET levels may predispose to disease, but disease could also lead to low ET levels. Possible reasons could include:

  • Alterations in diet due to illness so that less ET is consumed;
  • Decreases in ETT activity in the gut (leading to less ET uptake) or kidney (impairing ET reabsorption) with age and disease.
  • Changes in gut microbiota might influence uptake and accumulation in the body.
  • ET is being consumed as it scavenges oxygen radicals and other reactive oxygen species, the production of which is known to increase in these diseases and during ageing in general.

Only the gold standard of placebo-controlled double-blinded clinical studies can definitively establish the value (if any) of ET in preventing or treating human disease. Several such trials are being planned or in progress; we await the results with interest, and a streak of optimism.” “Ergothioneine, where are we now?”

One of the collection’s papers focused on what ETT research findings could or could not be replicated:

“ETT is not expressed ubiquitously and only cells with high ETT cell-surface levels can accumulate ET to high concentration. Without ETT, there is no uptake because the plasma membrane is essentially impermeable. We review substrate specificity and localization of ETT, which is prominently expressed in neutrophils, monocytes/macrophages, and developing erythrocytes.

Comparison of transport efficiency (TE) for acknowledged substrates of the ETT. Bar length represents approximate TE of wild-type human ETT.


We have not found in the literature any other ET transporters. However, it is highly probable that additional ET transporters work in the human body:

  • Uptake of ET from the small intestine into epithelial cells occurs through apically localized ETT. The very hydrophilic ET cannot then exit these cells toward the blood without help – a basolateral efflux transporter is required.
  • After oral administration of 3H-ET, a considerable amount of ET was still absorbed into the body in the ETT KO [knockout] mice. There must be another transporter for apical uptake at least in the small intestine of the mouse.
  • When ET was administered intravenously, ETT KO mice showed no change in ET concentration in the brain compared to wild type. The little ET that enters the brain must therefore pass through the BBB via a different transporter.” “The ergothioneine transporter (ETT): substrates and locations, an inventory”

It’s persuasive that there’s an evolutionarily conserved transmitter specific to ergothioneine. It isn’t persuasive that this compound once consumed is almost always in stand-by mode to do: what?

Ergothioneine isn’t a substitute for the related glutathione, especially since its supply isn’t similarly available from an endogenous source. It isn’t an active participant in day-to-day human life.

Still, I hedge my bets. I eat ergothioneine every day via white button mushrooms in AGE-less chicken vegetable soup at a cost of about $1.30.


Eat broccoli sprouts to epigenetically regulate histones

Five papers on beneficial effects from sulforaphane inhibiting histone deacetylases (HDACs), starting with a 2022 rodent cell study:

“Sulforaphane (SFN) has tissue specificity for subtypes of HDACs that are downregulated. For example:

  • In breast cancer cells, HDAC1-3 are inhibited by SFN to induce cell apoptosis;
  • In skin cells, HDAC1-4 are regulated by SFN [anti-skin cancer]; and
  • In the cochlea, SFN inhibits HDAC2, 4, and 5 [attenuates hearing loss].

In the present study, SFN significantly inhibited HDAC2, 3, and 5 expression and HDACs activity in cardiomyocytes, thereby increasing H3 acetylation levels in the Nrf2 promoter and upregulating Nrf2 expression. Mechanism by which SFN prevents Ang II-induced cardiomyocyte apoptosis:

  • Ang II activates oxidative stress by increasing ROS leading to inflammation, oxidative stress and fibrosis in cardiomyocytes.
  • SFN prevents Ang II-induced cardiomyocyte apoptosis by inhibiting HDACs to activate Nrf2 and downstream antioxidant genes.


SFN activates Nrf2 by inhibiting HDACs expression and activation.” “Sulforaphane inhibits angiotensin II-induced cardiomyocyte apoptosis by acetylation modification of Nrf2”

A 2021 rodent study found:

“SFN significantly attenuated diabetes-induced renal fibrosis in vivo. SFN inhibited diabetes-induced increase in HDAC2 activity.

Bone morphologic protein 7 (BMP-7) has been shown to reduce renal fibrosis induced by transforming growth factor-beta1. SFN protects against diabetes-induced renal fibrosis through epigenetic up-regulation of BMP-7.”

dmj-2020-0168f7 “Sulforaphane Ameliorates Diabetes-Induced Renal Fibrosis through Epigenetic Up-Regulation of BMP-7”

A 2019 human osteosarcoma cell study found:

“SFN inhibits mTOR in a concentration- and time-dependent manner. This inhibition occurs in the presence or in the absence of NRF2.

SFN inhibits HDAC6 and decreases catalytic activity of AKT, which partially explains the mechanism by which SFN inhibits mTOR.” “The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner”

A 2022 review cited a 2018 cell study:

“HDAC expression and activity are dysregulated in various diseases including asthma, chronic obstructive pulmonary disease, cancer, cardiac hypertrophy, and neurodegenerative and psychological disorders. HDAC inhibitors could be a potential therapeutic target for many diseases.

In hypertension, aortic stiffness is usually increased and vascular smooth muscle cells (VSMCs) contribute to vascular stiffness. We used VSMCs to test the degree of acetylation of histones in this study.

Sulforaphane weakly inhibited HDAC2 and effectively inhibited HDAC9.” “Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension” “Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat” (not freely available)


What do we know about human aging from mouse models?

Here is a 2021 rodent study and relevant parts from 3 of its 26 citing papers:

“A long line of evidence has established the laboratory mouse as the prime model of human aging. However, relatively little is known about detailed behavioral and functional changes that occur across their lifespan, and how this maps onto the phenotype of human aging.

To better understand age-related changes across the lifespan, we characterized functional aging in male C57BL/6J mice of five different ages (3, 6, 12, 18, and 22 months of age) using a multi-domain behavioral test battery. Assessment of functional aging in humans and mice: age-related patterns were determined based on representative data (Table 2), and then superimposed onto survival rate. (A) Body weight, (B) locomotor activity, (C) gait velocity, (D) grip strength, (E) trait anxiety, (F) memory requiring low attention level, and (G) memory requiring high attention level.


These functional alterations across ages are non-linear, and patterns are unique for each behavioral trait. Physical function progressively declines, starting as early as 6 months of age in mice, while cognitive function begins to decline later, with considerable impairment present at 22 months of age.

Functional aging of male C57BL/6J mice starts at younger relative ages compared to when it starts in humans. Our study suggests that human-equivalent ages of mice might be better determined on the basis of its functional capabilities.” “Functional Aging in Male C57BL/6J Mice Across the Life-Span: A Systematic Behavioral Analysis of Motor, Emotional, and Memory Function to Define an Aging Phenotype”

“Studies in mice show that physical function (i.e., locomotor activity, gait velocity, grip strength) begins to deteriorate around post-natal day (PND) 180, but cognitive functions (i.e., memory) do not exhibit impairment until roughly PND 660. Our results should be considered within the context of behavior changing throughout vole adulthood. Caution should be taken to avoid categorizing the oldest age group in our study as ‘elderly’ or ‘geriatric.'” “Behavioral trajectories of aging prairie voles (Microtus ochrogaster): Adapting behavior to social context wanes with advanced age”

“We used adult mice ranging in age from 5-6 months, not enough to modify experimental autoimmune encephalomyelitis progression. Mice are considered adult after 8 weeks; however, rapid growth for most biological processes is observed until 3 months of age, while past 6 months, mice might be affected by senescence.” “Age related immune modulation of experimental autoimmune encephalomyelitis in PINK1 knockout mice”

“Locomotor activity and gait velocity of 12 months old male C57BL/6 correlates with an elderly human being aged 60 or older, supporting that the ~15 months old mice we used in our study were aged mice at the time of tissue collection.” “Genomic Basis for Individual Differences in Susceptibility to the Neurotoxic Effects of Diesel Exhaust”


Do broccoli sprouts treat gout and kidney stones?

This 2022 rodent study investigated glucoraphanin’s effects on reducing uric acid:

“Hyperuricemia is a chronic disease characterized by abnormally elevated serum uric acid levels. Sulforaphane could lower uric acid by decreasing urate synthesis and increasing renal urate excretion in hyperuricemic rats.

A hyperuricemia model was established by administering feedstuffs with 4% potassium oxonate and 20% yeast. Forty male Sprague–Dawley rats were randomly divided into the normal control, hyperuricemia, allopurinol, and sulforaphane groups. Animals were treated by oral gavage for six consecutive weeks, and then phenotypic parameters, metabolomic profiling, and metagenomic sequencing were performed.


We identified succinic acid and oxoglutaric acid as critical host-gut microbiome co-metabolites. Sulforaphane improved diversity of microbial ecosystems and functions, as well as metabolic control of the kidney. Sulforaphane exerted its renoprotective effect through epigenetic modification of Nrf2 and interaction between gut microbiota and epigenetic modification in hyperuricemic rats.

Limitations of this study include:

  1. We used glucoraphanin bioactivated with myrosinase for our experiments. Future experiments may directly involve sulforaphane.
  2. Bioinformatics analysis resulted in speculations that require further experimental testing.
  3. Further investigation of interactions between microbiota and the host epigenome is still needed.” “Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia”

It was a stretch to label treatment subjects as the “sulforaphane group” by claiming “Glucoraphanin (10 mg/kg) was metabolized to SFN by myrosinase as described in previous studies.” Both this and the referenced 2014 study “(RS)-glucoraphanin purified from Tuscan black kale and bioactivated with myrosinase enzyme protects against cerebral ischemia/reperfusion injury in rats” measured glucoraphanin and myrosinase, but not sulforaphane.

A human equivalent to this study’s daily glucoraphanin intake of 10 mg / kg weight would be (.162 x 10 mg) x 70 kg = 113 mg. Whether 10 mg was dry or wet weight wasn’t disclosed.

If 10 mg was wet, 113 mg is a little more than twice our model clinical trial’s average glucoraphanin intake of 51 mg fresh weight from eating 30 grams / day of super sprouts. In April 2020’s Understanding a clinical trial’s broccoli sprout amount, a study coauthor said:

“We considered 30 g and 60 g to be 1/2 and 1 portion per day, respectively, of broccoli sprouts. When we carried out tests with consumers, previous to the bioavailability studies, higher amounts per day were not easy to consume and to get eaten by participants.”


Broccoli sprouts activate the AMPK pathway, Part 4

Today someone viewed the 2020 Part 3 of Broccoli sprouts activate the AMPK pathway which lacked citations at the time. Checking again, here are three citing 2022 papers, starting with a review:

“Nrf2 is an important transcription factor that regulates expression of a large number of genes in healthy and disease states. Nrf2 regulates expression of several key components of oxidative stress, mitochondrial biogenesis, mitophagy, autophagy, and mitochondrial function in all organs of the human body, and in the peripheral and central nervous systems.

Overall, therapeutic drugs including sulforaphane that target Nrf2 expression and Nrf2/ARE pathway are promising. This article proposes additional research in Nrf2’s role within Parkinson’s disease, Huntington’s disease, and ischemic stroke in preclinical mouse models and humans with age-related neurodegenerative diseases.” “Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases” (not freely available) Thanks to Dr. P. Hemachandra Reddy for providing a copy.

One of the Part 3 study’s coauthors contributed to this very detailed review:

“Due to observed overlapping cellular responses upon AMPK or NRF2 activation and common stressors impinging on both AMPK and NRF2 signaling, it is plausible to assume that AMPK and NRF2 signaling may interdepend and cooperate to readjust cellular homeostasis.


The outcome and underlying signaling events of AMPK-NRF2 crosstalk may diverge between:

  1. in vitro and in vivo studies (one cell type in isolation vs inter-organ crosstalk in living organisms);
  2. Different cell types/organs/organisms of different cultivation conditions, genetic background, age or sex;
  3. Different stress-regimens (chronic vs acute, nature of stress (lipotoxicity, redox stress, xenobiotic, starvation, etc));
  4. Different modes of Nrf2 or AMPK activation and inhibition (genetic vs pharmacological, constitutive vs transient/intermittent, systemic vs organ-specific, electrophilic vs PPI, allosteric vs covalent, or pan vs subtype-specific);
  5. Different target genes with distinct promoter and enhancer structure; or
  6. Different timing of activation.

The latter should deserve increased attention as Nrf2 is one of the most cycling genes under control of the circadian clock. Feeding behavior, metabolism and hence AMPK activity follow and substantiate the biological clock, indicating an entangled circadian regulation of metabolic and redox homeostasis.” “AMPK and NRF2: Interactive players in the same team for cellular homeostasis?”

A third citing paper was a study of lens cells that provided an example of similar metformin effects noted in Part 2 of Broccoli sprouts activate the AMPK pathway:

“Loss of Nrf2 and Nrf2 antioxidant genes expression and activity in aging cells leads to an array of oxidative-induced deleterious responses, impaired function, and aging pathologies. This deterioration is proposed to be the primary risk factor for age-related diseases such as cataracts.

AMPK regulates energy at physiological levels during metabolic imbalance and stress. AMPK is a redox sensing molecule, and can be activated under cellular accumulation of reactive oxygen species, which are endogenously produced due to loss of antioxidant enzymes.

The therapeutic potential of AMPK activation has context-dependent beneficial effects, from cell survival to cell death. AMPK activation was a requisite for Bmal1/Nrf2-antioxidants-mediated defense, as pharmacologically inactivating AMPK impeded metformin’s effect.

Using lens epithelial cell lines (LECs) of human or mouse aging primary LECs along with lenses as model systems, we demonstrated that metformin could correct deteriorated Bmal1/Nrf2/ARE pathway by reviving AMPK-activation and transcriptional activities of Bmal1/Nrf2, resulting in increased antioxidants enzymatic activity and expression of Phase II enzymes. Results uncovered crosstalk between AMPK and Bmal1/Nrf2/antioxidants mediated by metformin for blunting oxidative/aging-linked pathobiology.” “Obligatory Role of AMPK Activation and Antioxidant Defense Pathway in the Regulatory Effects of Metformin on Cellular Protection and Prevention of Lens Opacity”


Eat broccoli sprouts for longevity

This 2022 rodent study investigated effects of broccoli sprouts intake on health and longevity:

“The objective of this study was to assess effects of long-term broccoli sprouts (BrSp) feeding on longevity in rats, as well as on cardiometabolic health parameters. Twelve-week-old Long-Evans rats were randomized to control or BrSp groups.

Broccoli seeds were sprouted for 4 days then air dried for 7 days before use. Rats were fed 300 mg/kg body weight BrSp 3 days per week (Monday, Wednesday, Friday, to limit rat agitation) beginning at 4 months of age until death/euthanasia.

Mean age at death for the oldest 25% of male rats was higher in BrSp-fed rats (838 ± 18 days) than controls (754 ± 17 days). In females, BrSp feeding improved survival.


BrSp feeding of rodents starting at 4 months of age caused:

  1. Extended life span in rats, albeit this was observed predominantly in females;
  2. Reduced body weight gain in females;
  3. Modest improvements in glucose handling in males;
  4. Marked blood pressure reduction in males; and
  5. Modest changes in behavioral traits examined at 18 months in both sexes.

These findings highlight sex-dependent benefits of BrSp on improving longevity and delaying cardiometabolic decline associated with aging in rats.” “Broccoli Sprouts Promote Sex-Dependent Cardiometabolic Health and Longevity in Long-Evans Rats”

A human equivalent to this study’s dose is (.162 x 300 mg/kg)  x 70 kg = 3.4 grams dry weight three times a week. Per Drying broccoli sprouts, dried 3-day-old broccoli sprouts contain 10% moisture, and fresh 3-day-old broccoli sprouts contain 82.6% moisture. So 3.4 grams of broccoli sprout powder may be an approximate equivalent of 3.4 g x (.826 / .1) = 28 grams fresh broccoli sprouts.

Not sure why a dose regimen of “(Monday, Wednesday, Friday, to limit rat agitation)” was necessary, as that limited human applicability, lifespan results, and healthspan results. Still, this study was a step forward, and encouraged further lifespan and healthspan studies on broccoli sprout consumption.


Broccoli leaves and stems vs. highly-processed food

This 2022 rodent study investigated whether obesity caused by typical diets could be affected by adding a flour made of broccoli by-products:

“Obesity usually arises as a consequence of an excess of energy intake relative to the expense of energy via metabolic and physical activity. However, combinations of genetic, behavioral, and environmental factors can also contribute to obesity.

Broccoli by-products flour (BF) supplementation helped to maintain a lower body weight, reduced adipose tissue accumulation, and enhanced basal activity of superoxide dismutase and glutathione S-transferase.

treatment groups

  1. CTR – Western diet, control group;
  2. WD – Western diet plus 0.20% cholesterol;
  3. CTR+1.34BF – control diet containing 1.34% BF;
  4. WD+0.67BF – Western diet plus 0.20% cholesterol with 0.67% BF;
  5. WD+1.34BF – Western diet plus 0.20% cholesterol with 1.34% BF;
  6. WD+0.67BF(4w) – Western diet plus 0.20% cholesterol for 10 weeks and then fed with the corresponding diet supplemented with BF at 0.67% for 4 weeks;
  7. WD+1.34BF(4w) – Western diet plus 0.20% cholesterol for 10 weeks and then fed with the corresponding diet supplemented with BF at 1.34% for 4 weeks.

The dose of BF used in testing was established assuming that an adult person of 60 kg consumes around 150 g fresh broccoli per serving, which corresponds to around 19.05 g dry weight according to our laboratory. Consumption of 19.05 g BF per person corresponds to a dose of 317.5 mg/kg. Applying a dose conversion formula between humans (60 kg) and mice (20 g) (25), the equivalent dose will be 3905.25 mg/kg in a mouse, corresponding to around 78 mg BF/mouse.

Assuming that an adult person consumes on average 3 servings of broccoli per week, the intake of 78 mg BF three times a week is equivalent to the intake of 234 mg BF/week/mouse, corresponding to an average daily intake of 33.43 mg BF/mouse. For a mouse with a 5 g average daily food intake, this corresponds to 0.67% (w/w) of the daily feed.


Care must be taken with interpreting results obtained from preclinical animal models, as doses and administration protocols are often not comparable between experimental animals and humans. It is difficult to mimic the complexity of human diseases, and effective doses are different due to differences between species. Another limitation is concentrations of beneficial compounds may vary according to different climatic conditions, growing seasons, and cultivars.

BF appears to have a beneficial effect in preventing weight gain and fat accumulation induced by hypercholesterolemic diets.” “Beneficial Effects of Broccoli (Brassica oleracea var italica) By-products in Diet-induced Obese Mice”


If you were given a lens to see clearly, would you accept it?

Two papers, starting with a 2022 rodent study of maternal behaviors’ effects on offspring physiologies:

Early life adversity (ELA) is a major risk factor for development of pathology. Predictability of parental care may be a distinguishing feature of different forms of ELA.

We tested the hypothesis that changes in maternal behavior in mice would be contingent on the type of ELA experienced, directly comparing predictability of care in the limited bedding and nesting (LBN) and maternal separation (MS) paradigms. We then tested whether predictability of the ELA environment altered expression of corticotropin-releasing hormone (Crh), a sexually-dimorphic neuropeptide that regulates threat-related learning.

MS was associated with increased expression of Crh-related genes in males, but not females. LBN primarily increased expression of these genes in females, but not males.” “Resource scarcity but not maternal separation provokes unpredictable maternal care sequences in mice and both upregulate Crh-associated gene expression in the amygdala”

I came across this first study by it citing a republished version of 2005 epigenetic research from McGill University:

“Early experience permanently alters behavior and physiology. A critical question concerns the mechanism of these environmental programming effects.

We propose that epigenomic changes serve as an intermediate process that imprints dynamic environmental experiences on the fixed genome resulting in stable alterations in phenotype. These findings demonstrate that structural modifications of DNA can be established through environmental programming and that, in spite of the inherent stability of this epigenomic marker, it is dynamic and potentially reversible.” “Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome”

This post commemorates the five-year anniversary of Dr. Arthur Janov’s death. Its title is taken from my reaction to his comment on Beyond Belief: Symptoms of hopelessness. Search his blog for mentions of the second paper’s coauthors, Drs. Meaney and Szyf.


All about walnuts’ effects

Five 2022 papers focusing on walnuts, starting with a comparison of eight tree nuts:

“The aim of the present study was to examine 8 different popular nuts – pecan, pine, hazelnuts, pistachio, almonds, cashew, walnuts, and macadamia. Total content of phenolic compounds in nuts ranged from 5.9 (pistachio) to 432.9 (walnuts) mg/100 g.

Walnuts had the highest content of polymeric procyanidins, which are of great interest as important compounds in nutrition and biological activity, as they exhibit antioxidant, anti-inflammatory, antimicrobial, cardio- and neuroprotective action. Walnuts are good sources of fatty acids, especially omega-3 and omega-6.” “Nuts as functional foods: Variation of nutritional and phytochemical profiles and their in vitro bioactive properties”

A second study compared the same eight tree nuts plus Brazil nuts and peanuts:

“The highest total content of all analyzed flavonoids was determined in walnuts (114.861 µg/g) with epicatechin the most abundant, while the lowest was in almonds (1.717 µg/g). Epicatechin has antioxidant, anti-inflammatory, antitumor, and anti-diabetic properties. Epicatechin has beneficial effects on the nervous system, enhances muscle performance, and improves cardiac function.” “The Content of Phenolic Compounds and Mineral Elements in Edible Nuts”

Next, two systematic reviews and meta-analyses of human studies:

“We carried out a systematic review of cohort studies and randomized controlled trials (RCTs) investigating walnut consumption, compared with no or lower walnut consumption, including those with subjects from within the general population and those with existing health conditions, published from 2017 to 5 May 2021.

  • Evidence published since 2017 is consistent with previous research suggesting that walnut consumption improves lipid profiles and is associated with reduced CVD risk.
  • Evidence pointing to effects on blood pressure, inflammation, hemostatic markers, and glucose metabolism remains conflicting.
  • Evidence from human studies showing that walnut consumption may benefit cognitive health, which is needed to corroborate findings from animal studies, is now beginning to accumulate.” “Walnut consumption and health outcomes with public health relevance – a systematic review of cohort studies and randomized controlled trials published from 2017 to present”

“We aimed to perform a systematic review and meta-analysis of RCTs to thoroughly assess data concerning effects of walnut intake on selected markers of inflammation and metabolic syndrome in mature adults. Our findings showed that:

  • Walnut-enriched diets significantly decreased TG, TC, and LDL-C concentrations, while HDL-C levels were not significantly affected.
  • No significant changes were noticed on anthropometric, cardiometabolic, and glycemic indices after higher walnut consumption.
  • Inflammatory biomarkers did not record statistically significant results.” “Walnut Intake Interventions Targeting Biomarkers of Metabolic Syndrome and Inflammation in Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”

Finishing with a rodent study that gave subjects diabetes with a high-fat diet, then mixed two concentrations of walnut extract in with the treatment groups’ chow:

“This study was conducted to evaluate the protective effect of Gimcheon 1ho cultivar walnut (GC) on cerebral disorder by insulin resistance, oxidative stress, and inflammation in HFD-induced diabetic disorder mice. After HFD feed was supplied for 12 weeks, samples were orally ingested for 4 weeks to GC20 and GC50 groups (20 and 50 mg/kg of body weight, respectively).

  • Administration of GC improved mitochondrial membrane potential function, and suppressed oxidative stress in the brain.
  • GC inhibited hepatic and cerebral lipid peroxidation and the formation of serum AGEs, and increased serum antioxidant activity to improve HFD-induced oxidative stress.
  • The HFD group showed significant memory impairment in behavioral tests. On the other hand, administration of GC showed improvement in spatial learning and memory function.

walnut brain effects

Based on these physiological activities, GC showed protective effects against HFD-induced diabetic dysfunctions through complex and diverse pathways.” “Walnut Prevents Cognitive Impairment by Regulating the Synaptic and Mitochondrial Dysfunction via JNK Signaling and Apoptosis Pathway in High-Fat Diet-Induced C57BL/6 Mice”

How do you like my sand art?PXL_20221016_154923750

Eat broccoli sprouts to combat effects of BPA?

This 2022 rodent study investigated abilities of both glucoraphanin and sulforaphane to reduce bisphenol A’s effects:

“There are only a few studies on the anti-obesogenic activity of sulforaphane (SFN) in bisphenol A (BPA)-induced obese C57BL/6J mice and 3T3-L1 cells. BPA is one of the endocrine disrupting chemicals that mimics bioidentical hormones and acts as an active agonist of glucocorticoid receptors to promote adipogenesis.

We investigated anti-obesogenic effects of broccoli sprouts powder (BSP) with a high glucoraphanin (GRA) content, mustard (Sinapis alba L.) seed powder (MSP) that has a high myrosinase activity, and sulforaphane-rich MSP-BSP mixture powder (MBP).

  • GRA content in BSP was 131.11 ± 1.84 μmol/g, and SFN was not detected.
  • SFN content in MBP was 162.29 ± 1.24 μmol/g, and GRA was not detected.
  • GRA and SFN were not detected in MSP.

Mice were administered:

  • BPA (500 μg/kg/day);
  • BPA supplemented with 100 mg/kg/day Gar (BPA + Gar);
  • 15 mg/kg/day MSP (BPA + MSP);
  • 150 mg/kg/day BSP (BPA + BSP); or
  • 100 mg/kg/day MBP (BPA + MBP)

for 12 weeks. The BPA + Gar group served as the positive control group, since studies showed that Garcinia cambogia extract induces weight loss.

bpa weight gain

Mice in the BPA group showed a significantly high body weight and epididymal adipose tissue weight, compared to the ND group mice. MSP treatment had no significant effects. Gar, BSP, and MBP treatment significantly decreased body weight and epididymal adipose tissue weight in BPA-induced obese mice.

BSP and MBP exert anti-obesogenic effects by activating the AMPK signaling pathway. Our results suggest that BSP and MBP could be effective in the treatment and prevention of BPA-induced obesity.” “Anti-Obesogenic Effects of Sulforaphane-Rich Broccoli (Brassica oleracea var. italica) Sprouts and Myrosinase-Rich Mustard (Sinapis alba L.) Seeds In Vitro and In Vivo”

Human daily equivalent doses:

  • Sulforaphane was (.081 * 100 mg) x 70 kg = 567 mg, or (.567 g * 162.29 μmol/g) = 92 μmol. The μmol amount is reasonable, but the mg weight would be intolerable. I’ve contacted these researchers for clarification, and will update with their response.
  • Glucoraphanin in broccoli sprout powder at (.081 * 150 mg) x 70 kg = 851 mg looks reasonable. Broccoli sprout powder vendors recommend 1 gram.


Gut microbiota, SCFAs, and hypertension

Two 2022 rodent studies from the same research group on short-chain fatty acid effects, beginning with butyrate:

“Maternal nutrition, gut microbiome composition, and metabolites derived from gut microbiota are closely related to development of hypertension in offspring. A plethora of metabolites generated from diverse tryptophan metabolic pathways show both beneficial and harmful effects.

Butyrate, one of the short-chain fatty acids (SCFAs), has shown vasodilation effects. We examined whether sodium butyrate administration in pregnancy and lactation can prevent hypertension induced by a maternal tryptophan-free diet in adult progeny, and explored protective mechanisms.

Decreased tryptophan metabolites indole-3-acetamide and indoleacetic acid observed in offspring born to dams that received the trytophan-free (TF) diet coincided with hypertension. This suggested that gut microbiota-derived tryptophan metabolites might be an offsetting mechanism, but not a cause of TF-induced hypertension. Considering that TF intervention reduced abundance of Romboutsia and Akkermansia, and many species are able to metabolize tryptophan, further studies linking abundance of bacterial species and concentrations of tryptophan metabolites are still required to identify main tryptophan metabolite producers.

Sodium butyrate treatment during pregnancy and lactation offset effects of maternal tryptophan-deficiency-induced offspring hypertension, mainly related to shaping gut microbiome, mediating SCFA receptor GPR41 and GPE109A, and restoring the renin–angiotensin system. A better understanding of mechanisms behind tryptophan metabolism implicated in programming of hypertension is critical for developing gut microbiota-targeted therapies to halt hypertension.” “Sodium butyrate modulates blood pressure and gut microbiota in maternal tryptophan-free diet-induced hypertension rat offspring” (not freely available) Thanks to Dr. You-Lin Tain for providing a copy.

A second study was on propionate effects:

“Early-life disturbance of gut microbiota has an impact on adult disease in later life. Propionate, one of predominant SCFAs, has been shown to have antihypertensive property.

We examined whether perinatal propionate supplementation can prevent offspring hypertension induced by maternal chronic kidney disease (CKD). CKD is closely linked to adverse maternal and fetal outcomes, and is reported to affect at least 3%-4% women of childbearing age.

Male offspring were divided into four groups: control, CKD, control+propionate (CP), and CKD+propionate (CKDP).


Perinatal propionate supplementation:

  • Prevented offspring hypertension;
  • Shaped gut microbiota with increases in species richness and evenness;
  • Increased plasma propionate level; and
  • Upregulated renal GPR41 expression.

Results reveal the feasibility of manipulating gut microbiota by altering their metabolites with early-life use of propionate to prevent offspring hypertension in later life.” “Perinatal Propionate Supplementation Protects Adult Male Offspring from Maternal Chronic Kidney Disease-Induced Hypertension”